---
title: "Synbiotic Supplementation and Psychobiotic Diet for Depression and Anxiety in Gestational Diabetes"
id: "bmj-open-6-effect-of-synbiotic-supplementation-and-psychobiotic-diet-on-prenatal-and"
canonical_url: "https://medichelpline.com/clinical-feed/bmj-open-6-effect-of-synbiotic-supplementation-and-psychobiotic-diet-on-prenatal-and"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "BMJ Open"
source_url: "http://bmjopen.bmj.com/cgi/content/short/16/9/e118047?rss=1"
published_at: "2026-09-16T13:30:50.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Synbiotic Supplementation and Psychobiotic Diet for Depression and Anxiety in Gestational Diabetes
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/bmj-open-6-effect-of-synbiotic-supplementation-and-psychobiotic-diet-on-prenatal-and
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** BMJ Open
- **Source URL:** [Original Journal Publication](http://bmjopen.bmj.com/cgi/content/short/16/9/e118047?rss=1)
- **Published At:** 2026-09-16T13:30:50.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Gestational diabetes mellitus (**GDM**) is a common pregnancy metabolic disorder linked to higher rates of **anxiety** and **depression**, reported at two to four times those of healthy pregnancies. - The trial tests whether **psychobiotics**—delivered as a **synbiotic supplement** or via a **psychobiotic diet**—can prevent antenatal and postnatal mood and anxiety symptoms in women with GDM who have no clinically significant psychiatric symptoms at baseline. - Primary outcomes are **antenatal depression** and **pregnancy-related anxiety** at 38 weeks’ gestation; secondary outcomes include postpartum depression and anxiety at 4–6 weeks postpartum, maternal metabolic indices at 38 weeks, and selected maternal and neonatal outcomes immediately after birth. - Design: randomized, controlled, three-arm parallel trial with 102 pregnant women with GDM (diagnosed 24–28 weeks), randomized 1:1:1 to synbiotic capsule, psychobiotic diet, or placebo capsule. - Interventions start at GDM diagnosis (~28 weeks gestation) and continue until 4 weeks postpartum; all participants receive a standardised healthy diet education session per Iranian Ministry of Health guidelines. - Allocation uses block randomisation stratified by parity; analyses will follow a modified intention-to-treat approach with a per-protocol analysis for participants with ≥90% adherence. - Outcome measures include validated questionnaires: Edinburgh Postnatal Depression Scale, Revised Pregnancy-Related Anxiety Questionnaire, Postpartum Specific Anxiety Scale–Research Short Form, plus laboratory data, medical records, and a 3-day dietary record. - Ethics approval was obtained from Tabriz University of Medical Sciences (IR.TBZMED.RCE.1404.565); trial registered IRCT20220926056046N7. Details such as exact synbiotic formulation, psychobiotic diet components, blinding procedures, sample size calculation specifics and data monitoring arrangements were not reported in the source.
## Clinical Analysis & Structured Key Points
Background Gestational diabetes mellitus (GDM) is one of the most prevalent metabolic disorders during pregnancy and may lead to various short-term and long-term complications for both the mother and the fetus. It is also associated with psychological disorders, such as anxiety and depression, the prevalence of which is reported to be two to four times higher than that among healthy pregnant women. Psychobiotics may improve cognitive and emotional function through modulation of the gut - brain axis. Therefore, this study was designed to evaluate the prophylactic effects of synbiotic supplementation and a psychobiotic diet during pregnancy in women with GDM who do not have clinically significant depressive symptoms or psychiatric disorders at baseline. The primary outcomes are antenatal depression and pregnancy-related anxiety at 38 weeks of gestation; secondary outcomes include postpartum depression and anxiety at 4 - 6 weeks after birth, maternal metabolic indices at 38 weeks of gestation and selected maternal and neonatal outcomes assessed immediately after birth. Methods and analysis This is a randomised, controlled, three-arm parallel trial. A total of 102 pregnant women diagnosed with GDM between 24 and 28 weeks of gestation will be randomly assigned (1:1:1) to one of three groups: a synbiotic capsule (Group 1), a psychobiotic diet (Group 2) and a placebo capsule (control group). Allocation will be performed using block randomisation, stratified by parity. Regardless of group assignment, all participants will receive a standardised healthy diet education session in accordance with the Iranian Ministry of Health protocols. The intervention will be administered from the time of GDM diagnosis (28 weeks of gestation) until 4 weeks postpartum. Outcomes will be assessed through maternal and neonatal medical records, laboratory analyses, the Edinburgh Postnatal Depression Scale, Revised Pregnancy-Related Anxiety Questionnaire, Postpartum Specific Anxiety Scale-Research Short Form and a 3 day dietary food record. Data analysis will be performed according to the modified intention-to-treat approach. Additionally, a per-protocol analysis will be conducted for participants with an adherence rate of ≥90%. Ethics and dissemination The study protocol has been approved by the Ethics Committee of Tabriz University of Medical Sciences (IR.TBZMED.RCE.1404.565). Findings will be disseminated through peer-reviewed journals and presentations at relevant scientific conferences. Trial registration IRCT20220926056046N7
## Related Clinical Research

- [North West London Diabetes Cohort: multiethnic EHR resource for diabetes complications research](https://medichelpline.com/clinical-feed/bmj-open-2-large-scale-multiethnic-electronic-health-record-resource-for-diabetes.md)
- [Sex-specific trajectories to cardio-renal and mental health outcomes after type 2 diabetes onset](https://medichelpline.com/clinical-feed/plos-medicine-1-sex-differences-in-trajectories-to-cardio-renal-and-mental-health-outcomes.md)
- [ENDO 2026: Progress and Resilience in Endocrinology and Obesity Care](https://medichelpline.com/clinical-feed/endocrine-news-0-endo-2026-progress-and-resilience.md)
- [Understanding Parasitic Identification in Delusional Parasitosis](https://medichelpline.com/clinical-feed/plos-one-21-bridging-perception-and-reality-parasitic-identification-in-delusional.md)
- [Intraoperative frozen section for Bethesda III thyroid nodules: sensitivity, specificity, and clin](https://medichelpline.com/clinical-feed/medrxiv-12-diagnostic-accuracy-of-intraoperative-frozen-section-in-thyroid-nodules-with.md)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.